EGFR and cancer: An early application of this was the epidermal growth factor receptor (EGFR), abnormally activated in cancer, against which the two classes of anti-EGFR agents, monoclonal antibodies and low-molecular-weight tyrosine kinase inhibitors, showed antitumor activity in patients.